Department of Vascular diseases, Oslo University Hosptital, Aker
Oslo, 0586, Norway
NCT Number: NCT03547817
Recent studies have shown that applying intermittent negative pressure (INP) with short negative pressure (-40 mmHg) pulses to the lower extremities increase arterial blood flow velocity and skin blood flow. However, the optimal magnitude of negative pressure to improve blood flow is not known, and needs further investigation. Peripheral arterial blood flow velocity, skin blood flow and skin temperature in the foot will be recorded at different levels of oscillating negative pressure to identify a pressure range which is practically, while at the same time induce clinically relevant changes in blood flow parameters. Heart rate and blood pressure will be recorded to monitor the effects on the central circulation.
Looking for future studies?
Notify Me18 year–96 year
All sexes
Interventional
Not applicable
Oslo, 0586, Norway
Cross sectional study design. The equipment for physiological measurements will be attached to the patient, and the foot will then be placed in the pressure chamber. The device induces pulses of 10 sec negative pressure, and 7 sec of atmospheric pressure. Pressure levels of 0 mmHg, -10mmHg, -20 mmHg, -40 mmHg and -60 mmHg will be tested.
Patients will be recruited from the out-patient clinic at Department of Vascular Surgery, Oslo University Hospital, Aker.
Inclusion criteria
Diagnosed peripheral artery disease (PAD), Ankle-Brachial Index <0.9 Outcome measures:
Arterial blood flow: Ultrasound Doppler from peripheral arteries in the foot.
Skin blood flow: Laser Doppler to measure acral skin blood perfusion.
Skin temperature
Systemic blood pressure: Finger arterial pressure will continuously be acquired by a photoplethysmographic pressure recording device (Finometer).
Ankle brachial index
Pressure recordings inside the pressure chamber: Continuously monitoring of pressure within the pressure chamber using a digital differential manometer.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Pressure levels of 0 mmHg, -10 mmHg, -20 mmHg, -40 mmHg and -60 mmHg will be tested, with washout periods of 5 minutes between the different pressure levels
Time frame: At time of intervention
Continuously Ultrasound Doppler measurements of the dorsalis pedis artery or tibialis posterior artery to monitor changes in arterial blood flow during 5 min sequences of intermittent negative pressure treatment. Pressure levels of 0, -10 mmHg, -20 mmHg, -40 mmHg and -60 mmHg will be tested. Systolic pressures in the arm and the ankle will be assessed before the intervention to describe the patients severity of disease.
Time frame: At time of intervention
Continuously Laser Doppler measurements from the pulp of the first toe to monitor changes in acral skin perfusion during 5 min sequences of intermittent negative pressure treatment. Pressure levels of 0, -10 mmHg, -20 mmHg, -40 mmHg and -60 mmHg will be tested.
Oslo University Hospital
Other
Intermittent Negative Pressure to Improve Blood Flow in Patients With Peripheral Artery Disease. An Experimental Study to Investigate the Optimal Pulse Pressure Regime to Improve Blood Flow.
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04853719
Arterial Occlusive Diseases, Arteriosclerosis
Santo André, São Paulo, Brazil
View Trial DetailsNCT05059899
Arterial Occlusive Diseases, Arteriosclerosis
Coventry, West Midlands, United Kingdom
View Trial DetailsNCT04043546
Arterial Occlusive Diseases, Arteriosclerosis
Leuven, Belgium
View Trial DetailsNCT01131013
Arterial Occlusive Diseases, Arteriosclerosis
Phoenix, Arizona, United States
View Trial Details